User menu

EANM procedure guidelines for brain neurotransmission SPECT/PET using dopamine D2 receptor ligands, version 2.

Bibliographic reference Van Laere, Koen ; Varrone, Andrea ; Booij, Jan ; Nobili, Flavio ; Kapucu, Ozlem L ; et. al. EANM procedure guidelines for brain neurotransmission SPECT/PET using dopamine D2 receptor ligands, version 2.. In: European journal of nuclear medicine and molecular imaging, Vol. 37, no. 2, p. 434-342 (2010)
Permanent URL http://hdl.handle.net/2078.1/29644
  1. Tatsch Klaus, Can SPET imaging of dopamine uptake sites replace PET imaging in Parkinson’s disease? : For, 10.1007/s00259-002-0814-5
  2. Society of Nuclear Medicine Brain Imaging Council. Ethical clinical practice of functional brain imaging. J Nucl Med. 1996;37:1256–9.
  3. Elsinga PH, Hatano K, Ishiwata K. PET tracers for imaging of the dopaminergic system. Curr Med Chem. 2006;13:2139–53.
  4. Mukherjee J, Yang ZY, Das MK, Brown T. Fluorinated benzamide neuroleptics – III. Development of (S)-N-[(1-allyl-2-pyrrolidinyl)methyl]-5-(3-[18F]fluoropropyl)-2,3-dimethoxybenzamide as an improved dopamine D-2 receptor tracer. Nucl Med Biol. 1995;22:283–96.
  5. Schreckenberger M, Hagele S, Siessmeier T, et al. The dopamine D2 receptor ligand 18F-desmethoxyfallypride: an appropriate fluorinated PET tracer for the differential diagnosis of parkinsonism. Eur J Nucl Med Mol Imaging. 2004;31:1128–35.
  6. Farde L, Ehrin E, Eriksson L, et al. Substituted benzamides as ligands for visualization of dopamine receptor binding in the human brain by positron emission tomography. Proc Natl Acad Sci U S A. 1985;82:3863–7.
  7. Lindsey KP, Gatley SJ. Applications of clinical dopamine imaging. Neuroimaging Clin N Am. 2006;16:553–73, vii–viii
  8. Ravina B., Eidelberg D., Ahlskog J. E., Albin R. L., Brooks D. J., Carbon M., Dhawan V., Feigin A., Fahn S., Guttman M., Gwinn-Hardy K., McFarland H., Innis R., Katz R. G., Kieburtz K., Kish S. J., Lange N., Langston J. W., Marek K., Morin L., Moy C., Murphy D., Oertel W. H., Oliver G., Palesch Y., Powers W., Seibyl J., Sethi K. D., Shults C. W., Sheehy P., Stoessl A. J., Holloway R., The role of radiotracer imaging in Parkinson disease, 10.1212/01.wnl.0000149403.14458.7f
  9. Thobois S, Jahanshahi M, Pinto S, Frackowiak R, Limousin-Dowsey P. PET and SPECT functional imaging studies in Parkinsonian syndromes: from the lesion to its consequences. Neuroimage. 2004;23:1–16.
  10. Booij J, Knol RJ. SPECT imaging of the dopaminergic system in (premotor) Parkinson’s disease. Parkinsonism Relat Disord. 2007;13(Suppl 3):S425–8.
  11. Halldin C, Gulyas B, Langer O, Farde L. Brain radioligands – state of the art and new trends. Q J Nucl Med. 2001;45:139–52.
  12. Pinborg LH, Videbaek C, Knudsen GM, et al. Dopamine D(2) receptor quantification in extrastriatal brain regions using [(123)I]epidepride with bolus/infusion. Synapse. 2000;36:322–9.
  13. Knudsen GM, Karlsborg M, Thomsen G, et al. Imaging of dopamine transporters and D2 receptors in patients with Parkinson's disease and multiple system atrophy. Eur J Nucl Med Mol Imaging. 2004;31:1631–8.
  14. Ghaemi M, Hilker R, Rudolf J, Sobesky J, Heiss WD. Differentiating multiple system atrophy from Parkinson's disease: contribution of striatal and midbrain MRI volumetry and multi-tracer PET imaging. J Neurol Neurosurg Psychiatry. 2002;73:517–23.
  15. Oyanagi C, Katsumi Y, Hanakawa T, et al. Comparison of striatal dopamine D2 receptors in Parkinson's disease and progressive supranuclear palsy patients using [123I] iodobenzofuran single-photon emission computed tomography. J Neuroimaging. 2002;12:316–24.
  16. Kim YJ, Ichise M, Ballinger JR, et al. Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP. Mov Disord. 2002;17:303–12.
  17. Antonini A, Leenders KL, Vontobel P, et al. Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson’s disease. Brain. 1997;120(Pt 12):2187–95.
  18. Pirker W, Asenbaum S, Wenger S, et al. Iodine-123-epidepride-SPECT: studies in Parkinson’s disease, multiple system atrophy and Huntington’s disease. J Nucl Med. 1997;38:1711–7.
  19. Plotkin M, Amthauer H, Klaffke S, et al. Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients. J Neural Transm. 2005;112:677–92.
  20. Pani L, Pira L, Marchese G. Antipsychotic efficacy: relationship to optimal D2-receptor occupancy. Eur Psychiatry. 2007;22:267–75.
  21. Scherer J, Tatsch K, Schwarz J, Oertel W, Kirsch MC, Albus M. Striatal D2-dopamine receptor occupancy during treatment with typical and atypical neuroleptics. Biol Psychiatry. 1994;36:627–9.
  22. [123I]IBZM SPECT for imaging of striatal D2 dopamine receptors in 56 schizophrenic patients taking various neuroleptics, 10.1176/ajp.153.2.183
  23. Ichise M, Toyama H, Fornazzari L, Ballinger JR, Kirsh JC. Iodine-123-IBZM dopamine D2 receptor and technetium-99m-HMPAO brain perfusion SPECT in the evaluation of patients with and subjects at risk for Huntington’s disease. J Nucl Med. 1993;34:1274–81.
  24. Ginovart N, Lundin A, Farde L, et al. PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington’s disease. Brain. 1997;120(Pt 3):503–14.
  25. Oertel WH, Tatsch K, Schwarz J, et al. Decrease of D2 receptors indicated by 123I-iodobenzamide single-photon emission computed tomography relates to neurological deficit in treated Wilson’s disease. Ann Neurol. 1992;32:743–8.
  26. Muhr C. Positron emission tomography in acromegaly and other pituitary adenoma patients. Neuroendocrinology. 2006;83:205–10.
  27. Heiss WD, Herholz K. Brain receptor imaging. J Nucl Med. 2006;47:302–12.
  28. Rinne Juha O., Hietala Jarmo, Ruotsalainen Ulla, Säkö Erkki, Laihinen Arto, Någren Kjell, Lehikoinen Pertti, Oikonen Vesa, Syvälahti Erkka, Decrease in Human Striatal Dopamine D2 Receptor Density with Age: A PET Study with [11C]Raclopride, 10.1038/jcbfm.1993.39
  29. Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage. 1996;4:153–8.
  30. Calvini P, Rodriguez G, Inguglia F, Mignone A, Guerra UP, Nobili F. The basal ganglia matching tools package for striatal uptake semi-quantification: description and validation. Eur J Nucl Med Mol Imaging. 2007;34:1240–53.
  31. Popperl G, Radau P, Linke R, Hahn K, Tatsch K. Diagnostic performance of a 3-D automated quantification method of dopamine D2 receptor SPECT studies in the differential diagnosis of parkinsonism. Nucl Med Commun. 2005;26:39–43.
  32. Radau PE, Linke R, Slomka PJ, Tatsch K. Optimization of automated quantification of 123I-IBZM uptake in the striatum applied to parkinsonism. J Nucl Med. 2000;41:220–7.
  33. Zubal IG, Early M, Yuan O, Jennings D, Marek K, Seibyl JP. Optimized, automated striatal uptake analysis applied to SPECT brain scans of Parkinson’s disease patients. J Nucl Med. 2007;48:857–64.
  34. Buchert R, Berding G, Wilke F, et al. IBZM tool: a fully automated expert system for the evaluation of IBZM SPECT studies. Eur J Nucl Med Mol Imaging. 2006;33:1073–83.
  35. Slifstein M, Hwang DR, Martinez D, et al. Biodistribution and radiation dosimetry of the dopamine D2 ligand 11C-raclopride determined from human whole-body PET. J Nucl Med. 2006;47:313–9.
  36. Verhoeff Nicolaas P. L. G., Sokole Ellinor Busemann, Stabin Michael, Hengst Daan, Kung Hank F., Van Royen Eric A., Janssen Antonius G. M., Dosimetry of iodine-123 iodobenzamide in healthy volunteers, 10.1007/bf00180903
  37. Votaw JR, Ansari MS, Mason NS, et al. Dosimetry of iodine-123-epidepride: a dopamine D2 receptor ligand. J Nucl Med. 1995;36:1316–21.